Jamie J Kirkham1, Megan Bracken2, Lorna Hind2, Katie Pennington2, Mike Clarke3, Paula R Williamson2. 1. Department of Biostatistics, University of Liverpool, Liverpool, UK; Centre for Biostatistics, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. Electronic address: jamie.kirkham@manchester.ac.uk. 2. Department of Biostatistics, University of Liverpool, Liverpool, UK. 3. Northern Ireland Methodology Hub, Centre for Public Health, Queen's University Belfast, Belfast, UK.
Abstract
OBJECTIVES: The objective of this study was to assess the uptake of the rheumatoid arthritis core outcome set (RA-COS) using data from multiple data providers, and to investigate factors that may influence this uptake. STUDY DESIGN AND SETTING: An observational review was carried out on all clinical trials of rheumatoid arthritis that were indexed on the World Health Organization-International Clinical Trials Registry Platform (WHO-ICTRP). Various measures of COS uptake were calculated from information presented in the trial registries and trial publications. Logistic regression was conducted to investigate factors thought to be associated with planned COS uptake. RESULTS: A total of 341 trials were eligible for the evaluation of RA-COS uptake. In the decade leading up to 2019, the assessment of uptake based on published results was maintained at just over 80%. Trials that were not commercially funded were much less likely to plan to measure the RA-COS than those with industry funding (60% vs. 80%; adjusted OR 0.18, 95% CI 0.11 to 0.32; P < 0.001). CONCLUSION: This study has demonstrated that the use of the WHO-ICTRP can identify a large and geographically diverse range of trials to include in the evaluation of COS uptake.
OBJECTIVES: The objective of this study was to assess the uptake of the rheumatoid arthritis core outcome set (RA-COS) using data from multiple data providers, and to investigate factors that may influence this uptake. STUDY DESIGN AND SETTING: An observational review was carried out on all clinical trials of rheumatoid arthritis that were indexed on the World Health Organization-International Clinical Trials Registry Platform (WHO-ICTRP). Various measures of COS uptake were calculated from information presented in the trial registries and trial publications. Logistic regression was conducted to investigate factors thought to be associated with planned COS uptake. RESULTS: A total of 341 trials were eligible for the evaluation of RA-COS uptake. In the decade leading up to 2019, the assessment of uptake based on published results was maintained at just over 80%. Trials that were not commercially funded were much less likely to plan to measure the RA-COS than those with industry funding (60% vs. 80%; adjusted OR 0.18, 95% CI 0.11 to 0.32; P < 0.001). CONCLUSION: This study has demonstrated that the use of the WHO-ICTRP can identify a large and geographically diverse range of trials to include in the evaluation of COS uptake.
Authors: Andrea Monsour; Emma J Mew; Sagar Patel; Alyssandra Chee-A-Tow; Leena Saeed; Lucia Santos; Darren B Courtney; Priya N Watson; Suneeta Monga; Peter Szatmari; Martin Offringa; Nancy J Butcher Journal: BMC Med Res Methodol Date: 2020-05-25 Impact factor: 4.615
Authors: Bilal Alkhaffaf; Aleksandra Metryka; Jane M Blazeby; Anne-Marie Glenny; Paula R Williamson; Iain A Bruce Journal: PLoS One Date: 2021-12-31 Impact factor: 3.240
Authors: Caroline Miller; Jane Cross; Joel O'Sullivan; Dominic M Power; Derek Kyte; Christina Jerosch-Herold Journal: BMJ Open Date: 2021-07-30 Impact factor: 2.692